- Details
- Alicia Morgans facilitates a discussion with Heather Jacene and Oliver Sartor regarding the SNMMI consensus statement on the use of Lutetium PSMA-617 radionuclide therapy for advanced prostate cancer. This multidisciplinary consensus, crafted by nuclear medicine physicians and medical oncologists, dives deep into the complexities of the metastatic CRPC space. While Lutetium PSMA-617 emerges as a p...
|
- Details
- Zach Klaassen speaks with Abhishek Srivastava about the significance of germline and genomic testing in advanced prostate cancer. Dr. Srivastava elaborates on his recent publication, which aims to improve the penetration of such testing in urology, particularly in community practices. He emphasizes the importance of cascade testing for identifying actionable mutations and influencing treatment opt...
|
- Details
- Brandon Mahal discusses a large-scale, retrospective analysis involving nearly 12,000 patients, exploring comprehensive genomic profiling and treatment patterns in advanced prostate cancer across different ancestries. The study reveals significant variances in incidence and mortality by race and genomic ancestry, emphasizing a greater burden on men of African ancestry. It exposes how these men rec...
|
- Details
- Oliver Sartor discusses the REASSURE study with Alicia Morgans. The study investigates the long-term side effects of radium, the first approved alpha emitter, on prostate cancer patients. With over 1,400 patients involved, the study monitors side effects such as fractures, bone marrow failure, and secondary malignancies over the course of years. Interestingly, the study found fewer side effects th...
|
- Details
- In a discussion hosted by Andrea Miyahira, David Quigley discusses his team's research on the genomic and epigenomic landscape of double-negative metastatic prostate cancer. Dr. Quigley provides insights into the mechanisms behind the disease's resistance to targeted therapy, highlighting the transformation of prostate adenocarcinoma cells towards either maintaining their original nature or transi...
|
- Details
- Phillip Koo and Daniel Saltzstein delve into the ECLIPSE clinical trial. The trial, aiming to enroll over 400 patients, brings Lutetium-177, a radioligand therapy, to patients with metastatic castrate-resistant prostate cancer at an earlier stage than it's currently approved for. Dr. Saltzstein outlines the trial's inclusion criteria, notably patients with castrated testosterone, PSA progression,...
|
- Details
- David VanderWeele elucidates findings from the TALAPRO-2 study, emphasizing the substantial hazard ratio benefits observed in metastatic CRPC patients with HRR mutations, especially those with BRCA1 and 2 mutations, treated with enzalutamide combined with talazoparib. However, he raises questions regarding the true representation of the trial's population and a lack of subsequent PARP inhibitor tr...
|
- Details
- Alicia Morgans converses with Ravi Madan about an ongoing trial involving patients with biochemical recurrence of prostate cancer. The unique trial utilizes Prostate-Specific Membrane Antigen (PSMA) PET imaging to routinely monitor patients and to develop an understanding of the natural history of the disease in the context of recurrent prostate cancer. The goal is to prospectively monitor these p...
|
- Details
- Alicia Morgans hosts Sumit Subudhi to discuss underutilized therapies for metastatic castration-resistant prostate cancer (mCRPC). Dr. Subudhi expounds on the complexities of Sipuleucel-T and Radium-223, highlighting their benefits for maintaining patient quality of life. He clarifies that while these therapies do not reduce prostate-specific antigen (PSA) levels, they slow down cancer growth, exp...
|
- Details
- Alicia Morgans welcomes Boris Hadaschik to discuss the implications of using PSMA PET in non-metastatic castration-resistant prostate cancer treatment. Their focus lies on Dr. Hadaschik's presentation examining the long-term outcomes and clinical implications of this technology. His study refers to a 2019 dataset involving 200 men diagnosed with high-risk non-metastatic CRPC. Dr. Hadaschik explain...
|
